Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANIL K SOOD and SHANNON NEVILLE WESTIN.
ANIL K SOOD
Connection Strength
6.055
SHANNON NEVILLE WESTIN
  1. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2).
    View in: PubMed
    Score: 0.235
  2. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer. 2023 06 01; 129(11):1672-1680.
    View in: PubMed
    Score: 0.221
  3. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci. 2023 Feb 15; 24(4).
    View in: PubMed
    Score: 0.220
  4. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience. 2023 Feb 17; 26(2):106020.
    View in: PubMed
    Score: 0.219
  5. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82.
    View in: PubMed
    Score: 0.216
  6. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open. 2022 10 03; 5(10):e2236626.
    View in: PubMed
    Score: 0.214
  7. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89.
    View in: PubMed
    Score: 0.205
  8. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther. 2021 12; 20(12):2352-2361.
    View in: PubMed
    Score: 0.200
  9. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.199
  10. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. J Cancer Res Clin Oncol. 2021 Dec; 147(12):3545-3555.
    View in: PubMed
    Score: 0.199
  11. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
    View in: PubMed
    Score: 0.193
  12. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785.
    View in: PubMed
    Score: 0.191
  13. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112.
    View in: PubMed
    Score: 0.191
  14. Distinct T?cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. iScience. 2021 Feb 19; 24(2):102053.
    View in: PubMed
    Score: 0.190
  15. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97.
    View in: PubMed
    Score: 0.188
  16. Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. Int J Gynecol Cancer. 2021 02; 31(2):232-237.
    View in: PubMed
    Score: 0.188
  17. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
    View in: PubMed
    Score: 0.181
  18. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep. 2019 11 26; 9(1):17589.
    View in: PubMed
    Score: 0.176
  19. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530.
    View in: PubMed
    Score: 0.172
  20. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546.
    View in: PubMed
    Score: 0.170
  21. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490.
    View in: PubMed
    Score: 0.162
  22. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
    View in: PubMed
    Score: 0.162
  23. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.
    View in: PubMed
    Score: 0.161
  24. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46.
    View in: PubMed
    Score: 0.150
  25. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn. 2016 12; 16(12):1337-1351.
    View in: PubMed
    Score: 0.143
  26. UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Rep Med. 2024 Dec 17; 5(12):101834.
    View in: PubMed
    Score: 0.062
  27. The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy. Int J Gynecol Cancer. 2024 Oct 16.
    View in: PubMed
    Score: 0.062
  28. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. Gynecol Oncol. 2024 Nov; 190:283-290.
    View in: PubMed
    Score: 0.061
  29. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. 2024 Aug 10.
    View in: PubMed
    Score: 0.061
  30. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience. 2024 May 17; 27(5):109801.
    View in: PubMed
    Score: 0.060
  31. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med. 2024 Apr 12; 5(4):311-320.e3.
    View in: PubMed
    Score: 0.059
  32. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol. 2024 05; 230(5):544.e1-544.e13.
    View in: PubMed
    Score: 0.058
  33. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Rep Med. 2023 12 19; 4(12):101326.
    View in: PubMed
    Score: 0.058
  34. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
    View in: PubMed
    Score: 0.058
  35. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023 09 04; 33(9):1331-1344.
    View in: PubMed
    Score: 0.057
  36. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci Adv. 2023 07 21; 9(29):eadf7195.
    View in: PubMed
    Score: 0.057
  37. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol. 2023 06; 228(6):724.e1-724.e9.
    View in: PubMed
    Score: 0.055
  38. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.
    View in: PubMed
    Score: 0.054
  39. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer. Cancers (Basel). 2022 Jul 23; 14(15).
    View in: PubMed
    Score: 0.053
  40. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol. 2022 07; 166(1):50-56.
    View in: PubMed
    Score: 0.052
  41. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol. 2022 06; 165(3):560-567.
    View in: PubMed
    Score: 0.052
  42. Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. J Cancer Res Clin Oncol. 2022 Apr; 148(4):803-821.
    View in: PubMed
    Score: 0.051
  43. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol. 2021 08; 162(2):482-495.
    View in: PubMed
    Score: 0.049
  44. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel). 2021 Feb 09; 13(4).
    View in: PubMed
    Score: 0.048
  45. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62.
    View in: PubMed
    Score: 0.048
  46. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835.
    View in: PubMed
    Score: 0.048
  47. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol. 2020 09; 158(3):653-658.
    View in: PubMed
    Score: 0.046
  48. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432.
    View in: PubMed
    Score: 0.041
  49. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
    View in: PubMed
    Score: 0.035
  50. Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol. 2012 Apr; 125(1):252-5.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.